The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Biomarin Pharmaceutical Inc

Nasdaq: BMRN
Last

(U.S.) $82.21

Today's change-1.12 -1.34%
Updated December 2 4:00 PM EST. Delayed by at least 15 minutes.
 

Biomarin Pharmaceutical Inc

Nasdaq: BMRN
Last

(U.S.) $82.21

Today's change-1.12 -1.34%
Updated December 2 4:00 PM EST. Delayed by at least 15 minutes.

Biomarin Pharmaceutical Inc down (U.S.)$1.12

Biomarin Pharmaceutical Inc closed lower Friday, dropping (U.S.)$1.12 or 1.34% to (U.S.)$82.21. Over the last five days, shares have lost 7.63% and are down 21.53% for the last year to date. This security has underperformed the S&P 500 by 19.46% during the last year.

Key company metrics

  • Open(U.S.) $83.39
  • Previous close(U.S.) $83.33
  • High(U.S.) $84.02
  • Low(U.S.) $81.89
  • Bid / Ask(U.S.) $80.00 / (U.S.) $85.15
  • YTD % change-21.53%
  • Volume1,142,525
  • Average volume (10-day)1,125,855
  • Average volume (1-month)1,344,553
  • Average volume (3-month)1,454,226
  • 52-week range(U.S.) $62.12 to (U.S.) $107.56
  • Beta1.56
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$2.96
Updated December 2 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-46.22%

Although this company's net profit margin is negative, it is above the industry average and implies that Biomarin Pharmaceutical Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.17%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2016Q2/2016Q1/2016Q4/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015
Revenue280300237228
Total other revenue--------
Total revenue280300237228
Gross profit229249194185
Total cost of revenue51524343
Total operating expense340873318127
Selling / general / administrative12011098114
Research & development161167159176
Depreciation / amortization8888
Interest expense (income), net operating--------
Unusual expense (income)05990-171
Other operating expenses, total2-623-44
Operating income-60-573-81101
Interest income (expense), net non-operating-10-10-10-9
Gain (loss) on sale of assets--------
Other--------
Income before tax-67-583-8993
Income after tax-43-424-8569
Income tax, total-24-159-424
Net income-43-424-8569
Total adjustments to net income--------
Net income before extra. items-43-424-8569
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-43-424-8569
Inc. avail. to common incl. extra. items-43-424-8569
Diluted net income-43-424-8569
Dilution adjustment--------
Diluted weighted average shares168163162161
Diluted EPS excluding extraordinary itemsvalue per share-0.26-2.61-0.530.43
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share-0.26-0.21-0.53-0.26